subject: Nycomed S.c.a. Sicar: Pharmavitae Profile - Market Research Reports On Aarkstore Enterprise [print this page] Introduction Introduction
This analysis examines the historical and forecast performance for Nycomed in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
*Benchmark Nycomed's performance against key rivals in the prescription pharmaceutical sector
*Determine the historical impact of M&A on Nycomed's specialty pharmaceutical business model
*Examine Nycomed's growth potential in the face of a blockbuster patent expiry
Table of Contents :
"ABOUT HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
Nycomed: PharmaVitae forecasts at a glance 8
Strategic insight 9
Historical growth led by Altana acquisition 9
Near-term operating performance threatened by reduced pantoprazole sales 10
M&A extends geographical reach to global scale 10
SWOT analysis 11
Table of Contents 12
Table of figures 14
Chapter 3 Quarterly news update 15
Product developments 15
Deals and alliances 16
Product deals 16
Company announcements 17
Chapter 4 Company introduction 18
Key findings 18
Background 19
Key corporate developments 19
M&A history 20
Chapter 5 Company sales 22
Key findings 22
Prescription pharmaceutical sales and growth rate analysis, 2002-14 23
Product analysis 24
Product analysis, 2002-08 25
Product analysis, 2008-14 27
Therapy area analysis 30
Geographic analysis 32
Launch/core/expiry analysis 34
Explanation of launch/core/expiry analysis 34
Launch analysis, 2008-14 35
Core analysis, 2008-14 36
Expiry analysis, 2008-14 37
Launch/core/expiry configuration, 2008-14 38
Molecule type analysis 39
Externalization analysis 41
Chapter 6 Company financials 43
Key findings 43
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 44
Operating costs and profit analysis 45
Operating costs and profit analysis, 2002-08 46
Operating cost ratio and profit margin analysis, 2002-08 47
Operating cost ratio and profit margin analysis, 2008-14 48
Operating costs and profit analysis, 2008-14 49
Chapter 7 Key products and competitors 50
Key findings 50
Overview 51
Gastroenterology 52
Pantoprazole 52
Overview 52
Sales forecast 53
Sales remain strong despite generic encroachment in the US 54
Efficacy favors Protonix in an already genericized market 55
Respiratory 56
Alvesco 56
Overview 56
Sales forecast 57
New once-daily inhaled corticosteroid for asthma 57
US licensing agreement reached with respiratory specialist Sepracor 57
Asthma market overview 57
Ciclesonide safety advantages could help overcome barriers to uptake 58
Alvesco forecast assumptions 59
Omnaris 60
Overview 60
Sales forecast 61
Allergic rhinitis launch adds significant value to franchise 61
Daxas 62
Overview 62
Sales forecast 63
Commercial attractiveness 65
Genitourinary 66
Preotact 66
Overview 66
Sales forecast 67
Novel medication for high fracture risk postmenopausal osteoporosis 67
Preotact offers novel administration and MOA 67
Chapter 8 Appendix 69
R&D pipeline 69
References 70
Abbreviations 70
Exchange rates 72
About 73
About Healthcare 73
consulting 73
Disclaimer 75
List of Tables
Table 1: Nycomed - PharmaVitae forecasts at a glance 8
Table 2: Nycomed operating cost ratio analysis (% of total revenues), 2002-08 9
